Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia; Lung Transplant Service, The Alfred Hospital and Monash University, Melbourne, Vic, Australia.
Lung Transplant Service, The Alfred Hospital and Monash University, Melbourne, Vic, Australia.
Heart Lung Circ. 2022 Feb;31(2):285-291. doi: 10.1016/j.hlc.2021.05.094. Epub 2021 Jun 26.
In Australia, increased organ donation and subsequent lung transplantation (LTx) rates have followed enhanced donor identification, referral and management, as well as the introduction of a donation after circulatory death (DCD) pathway. However, the number of patients waiting for LTx still continues to exceed the number of lung donors and the search for further suitable donors is critical.
All 2014-2018 Victorian DonateLife hospital deaths after intensive care unit (ICU) admission were analysed retrospectively to quantify unrecognised lung donors using current criteria, as well as novel time-extended (90 mins-24 hrs post-withdrawal) DCD lung donors.
Using standard lung donor eligibility criteria, we identified 473 potential lung donors and a further 122 time-extended DCD potential lung donors among 3,538 patients meeting general eligibility criteria. Detailed review of end-of-life discussions with patient families and the reasons why they were not offered donation revealed several categories of additional lung donors-traditional lung donors missed in current practice (n=2); hepatitis C infected lung donors potentially treatable with direct-acting antivirals (n=14), time-extended DCD lung donors (n=60); donor lungs potentially suitable for transplant with use of ex-vivo lung perfusion (EVLP) (n=7).
While the number of lung donor opportunities missed under existing DonateLife donor identification and management processes was limited, a time-extended DCD lung donation pathway could substantially expand the lung donor pool. The use of hepatitis C infected donors, and the possibility of EVLP to solve donor graft assessment or logistic issues, could also provide small additional lung donor opportunities.
在澳大利亚,通过加强供体识别、转介和管理,以及引入循环死亡后捐献(DCD)途径,器官捐献和随后的肺移植(LTx)率有所增加。然而,等待 LTx 的患者人数仍然超过肺供体人数,因此寻找更多合适的供体至关重要。
回顾性分析了所有 2014 年至 2018 年维多利亚州 ICU 入院后死于医院的 DonateLife 患者,以使用当前标准量化未识别的肺供体,以及新的时间延长(撤机后 90 分钟至 24 小时)DCD 肺供体。
使用标准的肺供体资格标准,我们在符合一般资格标准的 3538 名患者中确定了 473 名潜在的肺供体和 122 名时间延长的 DCD 潜在肺供体。详细审查了与患者家属进行的临终讨论以及他们未被提供捐献的原因,发现了几类额外的肺供体——在当前实践中错过的传统肺供体(n=2);可能通过直接作用抗病毒药物治疗的丙型肝炎感染肺供体(n=14)、时间延长的 DCD 肺供体(n=60);使用体外肺灌注(EVLP)可使供体肺适合移植的潜在供体肺(n=7)。
虽然在现有的 DonateLife 供体识别和管理过程中错过的肺供体机会数量有限,但时间延长的 DCD 肺捐献途径可以大大扩大肺供体库。使用丙型肝炎感染供体,以及 EVLP 解决供体移植物评估或物流问题的可能性,也可以提供少量额外的肺供体机会。